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Abstract
Background: Reduced glomerular filtration rate and increased asymmetric dimethylarginine (ADMA) are prevalent
in elderly people. However, most of the studies that have examined the association between the two conditions
were performed in patients with renal dysfunction, but not in the general elderly population. Thus, we investigated an
association between estimated glomerular filtration rate (eGFR) and ADMA concentration among community-dwelling
older Koreans.
Methods: A cross-sectional study was conducted on 269 men and 382 women (mean age, 71.6 years) enrolled in the
Korean Social Life, Health, and Aging Project (KSHAP), a population-based cohort study of health determinants in
elderly Koreans. We calculated eGFR using chronic kidney disease- Epidemiology Collaboration Group (CKD-EPI)
equation. ADMA concentration was measured by an enzyme-linked immunosorbent assay. The association between
eGFR and ADMA concentrations was analyzed by multiple linear regression models.
Results: The mean ADMA was significantly higher in people with eGFR< 60mL/min/1.73m2 (0.691 μmol/L) than in
those with eGFR≥60mL/min/1.73m2 (0.667 μmol/L, p = 0.013). The negative correlations between eGFR level and
ADMA concentrations were significant in men and women after adjusted age. After adjusting for potential confounders
which were sex, age, body surface, blood pressure, total and HDL cholesterol, diabetes, smoking, and drinking, eGFR levels
were inversely associated with ADMA concentrations both in men (β = − 0.0015, p = 0.005) and women (β = −
0.001, p = 0.039).
Conclusion: Our findings suggest that an inverse association exists between eGFR and ADMA concentrations
among the Korean elderly in a rural community.
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Background
The prevalence of chronic kidney disease has been in-
creasing among elderly people, because aging affects kid-
ney function and arterial stiffness [1, 2]. As the elasticity
of the blood vessels decreases, the surrounding blood
vessels cannot protect the cells of the kidneys [3]. Asym-
metric dimethylarginine (ADMA) is an endogenous ni-
tric oxide (NO) synthase inhibitor [4]. ADMA is
eliminated through renal excretion and is metabolized
by a dimethylarginine dimethylaminohydrolase (DDAH),
which is found in the tissues of the kidney, pancreas,
and blood vessels [5]. Therefore, the kidney plays an im-
portant role in maintaining reduced plasma ADMA con-
centrations. However, among elderly people, DDAH
secretion is decreased and ADMA concentration is in-
creased because of reduced kidney function due to aging.
Inhibiting NO synthase impairs endothelium-dependent
vasodilation, resulting in endothelial dysfunction [6].
Based on previous studies, we hypothesized that reduced
eGFR would elevate plasma ADMA concentrations in
elderly people. However, most of the previous papers
were conducted only for renal patients, and the relation-
ship between eGFR and ADMA concentrations in the
general healthy population has not been rigorously stud-
ied. Hence, we investigate the association between eGFR




Data for this study was collected from the Korean Social
Life, Health, and Aging Project (KSHAP) cohort study,
which started in 2011. The KSHAP study recruited indi-
viduals aged 60 years or older and their spouses living in
Township K located on Ganghwa Island, South Korea.
As of January 2013, the total population who lived in
Township K was estimated at 1864 people and 871 fam-
ilies. With the aid of township officers and after per-
forming a pilot study, a total of 860 people who aged
over 60 years and their spouses was identified as the tar-
get population of KSHAP. To obtain their consents and
perform questionnaires, we visited participants’ homes
individually. A total of 814 of the 860 community-
dwelling adults (response rate, 94.7%) participated in the
study and finished the questionnaire surveys between
December 2011 and July 2012 [7]. Among them, 698
people completed the KSHAP-Health Examination at a
public health center (n = 533) or at home (n = 165) [8].
In this paper, 47 were excluded for missing key variables,
such as eGFR (n = 23), plasma ADMA concentration
n = 19), and body mass index (BMI) (n = 5), leaving 651
people (269 men and 382 women) for this analysis. All
participants provided written informed consent.
Measurements
Our trained personnel interviewed participants using stan-
dardized questionnaire surveys according to a predefined
protocol. We obtained individuals’ socio-demographic
characteristics including age, education, occupation, reli-
gion, economic and marital status, smoking and drinking
habits, and medical history. Further detailed explanation
for this questionnaire was published in the cohort profile
paper [9].
Standing height was measured to the nearest 0.1 cm
with a stadiometer. We measured body weight to the
nearest 0.1 kg with a digital scale according to the
predefined manual. BMI was calculated as an individ-
ual’s body weight divided by height squared (kg/m2).
Body surface area (BSA) was calculated by a formula;
[{(weight) x (height)}/3600]1/2. We measured blood
pressure for two times using an automatic sphygmo-
manometer (Dinamap 1846 SX/P; GE Healthcare,
Waukesha, WI, USA) after participants rested for at
least five minutes in a seated position. If the two
measurements differed by 10 mmHg or more, add-
itional measurements were performed after five mi-
nutes [10]. The average of the last two measurements
was used in this study.
Individuals’ blood samples were collected after at least
eight hours’ fasting. Serum creatinine concentrations
were analyzed using a colorimetric Jaffe, Alkaline picrate,
kinetic method (ADVIA1800 Auto Analyzer, Siemens
Medical Sol., Deerfield, IL, USA). Concentrations of
blood urea nitrogen and glucose were analyzed using a
colorimetry-based method (ADVIA1800 Auto Analyzer,
Siemens Medical Sol., Deerfield, IL, USA). Fasting insu-
lin concentration was measured by using an immunora-
diometric assay (SR-300, Stratec, Germany). Total
cholesterol, high-density lipoprotein (HDL) cholesterol,
and triglyceride levels were assayed by enzymatic methods
(ADVIA1800 Auto Analyzer, Siemens Medical Sol., Deer-
field, IL, USA). Participants’ eGFR was calculated by
chronic kidney disease- Epidemiology Collaboration
Group (CKD-EPI) equation, which was developed and val-
idated in 2009 to predict CKD more accurately in people
with eGFR > 60ml/min/1.73m2 [11, 12]. The CKD-EPI
formula was shown in Fig. 1. Furthermore, all participants
were classified into two eGFR groups according to Na-
tional Kidney Foundation criteria: normal to minimally-
reduced eGFR (≥60ml/min /1.73m2) and moderately to
severely-reduced eGFR (< 60ml/min /1.73m2) [13]. In
addition, ADMA concentration was measured by an
enzyme-linked immunosorbent assay (Spectramax190,
Molecular Devices, USA). We decided that ADMA eleva-
tion corresponds to a concentration above the 75th per-
centile. Hypertension was defined as systolic blood
pressure (SBP) ≥140mmHg, diastolic blood pressure
(DBP) ≥90mmHg, or current use of anti-hypertensive
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Fig. 1 CKD-EPI equations for women and men
Table 1 General characteristics of study population in total, men, and women
Variables Total (n = 651) Men (n = 269) Women (n = 382) p-value
Age, yr 71.6 ± 7.5 72.2 ± 6.8 71.1 ± 7.9 0.061
Body mass index, kg/m2 24.0 ± 3.4 23.6 ± 3.4 24.3 ± 3.4 0.007
Body surface area 1.3 ± 0.3 1.4 ± 0.3 1.1 ± 0.2 < 0.001
eGFR, mL/min/1.73m2 67.7 [59.5, 76.2] 69.4 [61.0, 77.5] 65.9 [57.9, 74.3] 0.003
eGFR< 60 174 (26.7) 58 (21.6) 116 (30.4) 0.012
eGFR≥60 477 (73.3) 211 (78.4) 266 (69.6)
BUN, mg/dL 15.8 [13.1, 19.1] 16.6 [13.9, 19.3] 15.2 [12.7, 18.7] 0.001
Creatinine, mg/dL 0.95 [0.85, 1.09] 1.06 [0.97, 1.19] 0.88 [0.81, 0.98] < 0.001
ADMA, μmol/L 0.674 ± 0.111 0.677 ± 0.109 0.671 ± 0.112 0.542
ADMA elevation * 182 (28.0) 80 (12.3) 102 (15.7) 0.396
Systolic BP, mmHg 134.2 ± 20.1 132.9 ± 19.8 135.1 ± 20.3 0.165
Diastolic BP, mmHg 72 ± 10.1 73.1 ± 10.4 71.2 ± 9.9 0.023
Pulse pressure, bpm 62.2 ± 16.9 59.9 ± 15.8 63.9 ± 17.5 0.003
Fasting glucose, mg/dL 90 [83, 101] 91 [83, 106] 89 [83, 98] 0.034
Fasting insulin, uIU/mL 7.6 [5.9, 10.3] 7.0 [5.5, 10.4] 7.9 [6.2, 10.2] 0.006
Total cholesterol, mg/dL 181.9 ± 36 172.2 ± 34.6 188.7 ± 35.5 < 0.001
HDL cholesterol, mg/dL 50.9 ± 12.7 50.1 ± 13.3 51.5 ± 12.3 0.147
Triglycerides, mg/dL 136 [102, 188] 129 [94, 178] 141 [105, 193] 0.029
Diabetes, % 150 (23.0) 71 (26.4) 79 (20.7) 0.090
Hypertension, % 420 (64.5) 163 (60.6) 257 (67.3) 0.080
Hyperlipidemia, % 181 (27.8) 75 (27.9) 106 (27.8) 0.970
Smoking
Non-smoker 456 (70.0) 82 (30.5) 374 (97.9) < 0.001
Past smoker 117 (18.0) 117 (43.5) 0 (0.0)
Current smoker 78 (12.0) 70 (26.0) 8 (2.1)
Drinking
Non-drinker 512 (78.7) 154 (57.3) 358 (93.7) < 0.001
Current drinker 139 (21.3) 115 (42.7) 24 (6.3)
Values are shown as mean ± SD, median [IQR], or number (%)
eGFR, estimated glomerular filtration rate; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BUN, blood urea nitrogen; ADMA,
asymmetric dimethylarginine
* ADMA elevation, people with ADMA concentrations >75th percentile
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medicine. Diabetes was defined as fasting glucose ≥126
mg/dL or current use of oral anti-diabetic medicine or in-
sulin. Hypercholesterolemia was defined as total choles-
terol ≥240mg/dL, HDL cholesterol < 40mg/dL or current
treatment by anti-hyperlipidemic agents.
Statistical analysis
Sex differences of baseline characteristics were analyzed
by t-test for continuous variables and Chi-square test for
categorical variables. We also compared participants’
characteristics between groups of eGFR < 60 and ≥ 60
mL/min/1.73m2. Differences in general characteristics
among two groups were analyzed using t-test for con-
tinuous variables and Chi-square test for categorical var-
iables. Continuous variables that followed a normal
distribution are shown as mean and standard deviation,
whereas skewed variables are expressed as median and
interquartile range. Categorical variables were described
as numbers and percentages. Fasting glucose and insulin,
triglycerides, serum creatinine, and blood urea nitrogen
were log-transformed for parametric analysis due to the
right-skewed distributions.
Correlation between eGFR and ADMA concentrations
was assessed by Spearman’s coefficients in men and
women individually, because eGFR level was skewed to
right. To evaluate independent associations between
continuous eGFR and plasma ADMA concentration, we
carried out multiple linear regression analyses in three
adjusted models: model 1 was unadjusted analyses;
model 2 was adjusted for blood pressure, diabetes, total
cholesterol, HDL cholesterol, smoking status, and drink-
ing status; and model 3 was adjusted for sex, age, BMI,
blood pressure, diabetes, total cholesterol, HDL choles-
terol, smoking status, and drinking status.
Table 2 General characteristics in groups of eGFR< 60 and ≥ 60 mL/min/1.73m2
Variables Total (n = 651) eGFR< 60 (n = 174) eGFR≥60 (n = 477) p-value
Age, yr 71.6 ± 7.5 75.3 ± 7.8 70.1 ± 6.8 < 0.001
Body mass index, kg/m2 24.0 ± 3.4 23.7 ± 3.5 24.1 ± 3.4 0.247
Body surface area 1.3 ± 0.3 1.2 ± 0.3 1.3 ± 0.3 < 0.001
eGFR, mL/min/1.73m2 67.7 [59.5, 76.2] 53.0 [45.4, 57.0] 71.4 [66.2, 78.0] < 0.001
BUN, mg/dL 15.8 [13.1, 19.1] 18.1 [15.4, 23.3] 15.0 [12.6, 17.8] < 0.001
Creatinine, mg/dL 0.95 [0.85, 1.09] 1.17 [1.00, 1.34] 0.90 [0.83, 1.01] < 0.001
ADMA, μmol/L 0.674 ± 0.111 0.691 ± 0.112 0.667 ± 0.11 0.013
ADMA elevation * 182 (28.0) 57 (31.3) 125 (26.7) 0.237
Systolic BP, mmHg 134.2 ± 20.1 137.3 ± 21.6 133 ± 19.4 0.014
Diastolic BP, mmHg 72 ± 10.1 71.1 ± 10.5 72.3 ± 10 0.172
Pulse pressure, bpm 62.2 ± 16.9 67.2 ± 18.1 61.8 ± 14.2 0.003
Fasting glucose, mg/dL 90 [83, 101] 91 [84, 107] 89 [83, 99] 0.001
Fasting insulin, uIU/mL 7.6 [5.9, 10.3] 8.4 [6.2, 13.2] 7.4 [5.8, 9.9] 0.002
Total cholesterol, mg/dL 181.9 ± 36 175.3 ± 38.7 184.4 ± 34.7 0.003
HDL cholesterol, mg/dL 50.9 ± 12.7 48.6 ± 12.5 51.8 ± 12.7 0.004
Triglycerides, mg/dL 136 [102, 188] 149 [109, 193] 129 [100, 185] 0.844
Diabetes, % 150 (23.0) 55 (30.2) 95 (20.3) 0.008
Hypertension, % 420 (64.5) 139 (76.4) 281 (59.9) < 0.001
Hyperlipidemia, % 181 (27.8) 57 (31.3) 124 (26.4) 0.216
Smoking
Non-smoker 456 (70.0) 131 (72.0) 325 (69.3) 0.792
Past smoker 117 (18.0) 31 (17.0) 86 (18.3)
Current smoker 78 (12.0) 20 (11.0) 58 (12.4)
Drinking
Non-drinker 512 (78.7) 157 (86.3) 355 (75.7) 0.002
Current drinker 139 (21.3) 25 (13.7) 114 (24.3)
Values are shown as mean ± SD, median [IQR], or number (%)
eGFR, estimated glomerular filtration rate; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BUN, blood urea nitrogen; ADMA,
asymmetric dimethylarginine
* ADMA elevation, people with ADMA concentrations >75th percentile
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All analyses were performed with SAS version 9.4
(SAS Institute, Cary, NC, USA), and statistical signifi-
cance was defined as a two-sided p-value less than 0.05.
Results
Differences of baseline characteristics in total, men, and
women are described in Table 1. A total of 651 partici-
pants (269 men and 382 women) were included in this
study. The distributions of eGFR < 60mL/min/1.73m2
were 21.6% in men and 30.4% in women. The mean age
of men and women were 72.2 and 71.1 years old. Men
had significantly higher BSA, eGFR level, BUN, serum
creatinine concentrations, DBP, fasting glucose level,
and higher frequency of current smoker and drinker,
compared with women. On the other hand, the mean of
BMI, pulse pressure, fasting insulin, total cholesterol,
and triglycerides were significantly higher in women
than men. However, there were no significant differences
of ADMA concentrations between men and women.
Table 2 shows general characteristics of the study par-
ticipants according to eGFR groups; eGFR< 60 and ≥ 60
mL/min/1.73m2. The mean ADMA concentration was
significantly higher in people with eGFR < 60 mL/min/
1.73m2 (0.691 μmol/L, p = 0.013) compared to those with
eGFR ≥60mL/min/1.73m2 (0.667 μmol/L). Participants
with lower eGFR had significantly older age, higher
BUN, creatinine, SBP, pulse pressure, fasting glucose
and insulin level compared to those with higher eGFR.
The prevalence of diabetes and hypertension were sig-
nificantly higher in group of eGFR < 60 mL/min/1.73m2.
Figure 2 presents the correlation of eGFR and plasma
ADMA concentrations in men and women by using
Spearman’s coefficients with scatter plots. The eGFR was
negatively correlated with ADMA concentrations among
men in the unadjusted and age-adjusted models. In
women, the inverse correlation between eGFR and ADMA
concentrations was significant in age-adjusted model.
Table 3 outlines the linear association of continuous
eGFR and ADMA concentrations from multiple linear
regression analyses in total and groups stratified by
eGFR level. Among total participants, the negative asso-
ciation of eGFR and ADMA concentration was signifi-
cant in an unadjusted model. After fully adjusting for
sex, age, BSA, blood pressure, total and HDL cholesterol,
diabetes, smoking status, and alcohol consumption, the
eGFR was significantly and inversely associated with
ADMA concentration. In people with eGFR ≥60mL/
min/1.73m2, low eGFR was significantly associated with
high ADMA concentrations before and after multiple
adjusted. Although there were no statistical significant
association of eGFR with ADMA concentrations among
those with eGFR < 60 mL/min/1.73m2, the negative asso-
ciations were also presented before and after fully ad-
justed for confounders.
Table 4 also describes relationships between eGFR and
ADMA concentrations in men and women, using multiple
linear regression. Both of men and women had significant
and inverse associations of eGFR with ADMA plasma
concentrations regardless of adjustments for potential
confounders.
Discussion
We observed a significant independent association be-
tween eGFR and plasma ADMA concentrations in the
Fig. 2 Spearman’s correlations between eGFR levels and plasma ADMA concentrations
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elderly Korean population. We suggested that eGFR de-
cline might be a risk factor of endothelial dysfunction.
Even for the apparently healthy elderly with no known
kidney disease, reduced kidney function could predict
the increased risk of endothelial dysfunction.
Our results are consistent with the findings from previ-
ous studies [14–19]. According to a prospective study,
which was conducted for 227 patients with mild to mod-
erate kidney disease, ADMA concentrations were signifi-
cantly and negatively correlated with GFR, and positively
Table 3 Association between eGFR and ADMA concentrations in total participants groups stratified by eGFR level
Variables model 1 model 2 model 3
β (μmol/L) p value β (μmol/L) p value β (μmol/L) p value
Total participants
eGFR (mL/min/1.73m2) −0.0013 <.0001 −0.0013 0.000 −0.0013 0.000
Systolic BP (mmHg) − 0.0001 0.766 −0.0001 0.768
Diastolic BP (mmHg) −0.0001 0.872 −0.0001 0.868
Total cholesterol (mg/dL) 0.0000 0.896 0.0000 0.802
HDL cholesterol (mg/dL) 0.0000 0.952 0.0000 0.997
Diabetes Mellitus −0.0017 0.870 −0.0022 0.839
Current smokers (for non-smokers) 0.0221 0.001 0.0245 0.004
Current drinkers (for non-drinkers) − 0.0227 0.055 −0.0218 0.074
Sex 0.0075 0.595
Age (yr) 0.0001 0.912
BSA 0.0071 0.734
eGFR ≥ 60 (n = 477)
eGFR (mL/min/1.73m2) −0.0017 0.006 − 0.0017 0.005 − 0.0017 0.008
Systolic BP (mmHg) −0.0004 0.263 −0.0003 0.304
Diastolic BP (mmHg) 0.0000 0.979 −0.0001 0.917
Total cholesterol (mg/dL) 0.0000 0.892 0.0000 0.952
HDL cholesterol (mg/dL) −0.0001 0.812 −0.0001 0.903
Diabetes Mellitus 0.0075 0.552 0.0070 0.584
Current smokers (for non-smokers) 0.0211 0.008 0.0220 0.023
Current drinkers (for non-drinkers) −0.0257 0.052 −0.0263 0.057
Sex 0.0040 0.808
Age (yr) 0.0000 0.959
BSA 0.0111 0.646
eGFR < 60 (n = 174)
eGFR (mL/min/1.73m2) −0.0012 0.143 −0.0012 0.148 −0.0012 0.164
Systolic BP (mmHg) 0.0005 0.280 0.0005 0.319
Diastolic BP (mmHg) 0.0001 0.882 0.0001 0.948
Total cholesterol (mg/dL) −0.0001 0.550 −0.0002 0.533
HDL cholesterol (mg/dL) 0.0002 0.801 0.0002 0.825
Diabetes Mellitus −0.0226 0.244 −0.0219 0.292
Current smokers (for non-smokers) 0.0193 0.172 0.0235 0.205
Current drinkers (for non-drinkers) −0.0061 0.824 −0.0052 0.854
Sex 0.0093 0.761
Age (yr) −0.0001 0.943
BSA 0.0004 0.992
eGFR, estimated glomerular filtration rate; BP, blood pressure; HDL, high-density lipoprotein; BSA, body surface area
Model 1: unadjusted
Model 2: adjusted for blood pressure, total and HDL cholesterol, diabetes mellitus, smoking status, and drinking status
Model 3: adjusted for sex, age, BSA, blood pressure, total and HDL cholesterol, diabetes mellitus, smoking status, and drinking status
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correlated with age and serum creatinine. Mean ADMA
concentrations in advanced chronic kidney disease (CKD)
patients with GFR < 30ml/min/1.73m2 were significantly
higher than in CKD patients with GFR ≥ 90ml/min/1.73
m2. Furthermore, this study suggested that ADMA eleva-
tion was one of the factors that promotes the progression
of CKD [14]. A cross-sectional study in Australia was con-
ducted for 145 patients aged 40 to 74 with coronary artery
disease. Although this study included only patients with
GFR ≥ 45ml/min/1.73 m2, patients in the low GFR group
(GFR < 81ml/min/1.73m2) had significantly higher
ADMA concentrations, compared to patients in the high
GFR group (GFR ≥ 81ml/min/1.73m2). The association of
GFR and ADMA concentrations was also independent of
sex, age, and cigarette smoking habit [15].
In a subsequent Austrian study, patients with stage 4–
5 CKD (eGFR < 30 ml/min/1.73 m2) had significantly
higher ADMA concentrations than those with stage 2–3
CKD (eGFR ≥30 ml/min/1.73 m2). They also observed an
increase in plasma ADMA concentrations and a de-
crease in ADMA urinary excretion in patients with stage
4–5 CKD. Therefore, they suggested that reduced eGFR
might influence the high accumulation of plasma ADMA
concentrations and low excretion of ADMA in urine
[16]. According to a previous study which was con-
ducted for 218 general and diabetic hypertensive pa-
tients, ADMA concentrations were inversely correlated
with eGFR. They found that increases in ADMA con-
centrations during the follow-up period were signifi-
cantly associated with declines in eGFR and the
progression of CKD [17]. A previous paper observed
the differences in mean ADMA concentrations among
renal patients. In the results, CKD and dialysis pa-
tients had significantly higher ADMA compared to
the control group [18]. One cross-sectional study con-
sisting of Ghanaian patients with type 2 diabetes de-
termined that there was a significant association
between ADMA values and eGFR. Furthermore, this
study considered ADMA level as a novel biomarker
of renal dysfunction. They also suggested that a re-
duced eGFR in diabetic patients leads to an increase
in ADMA concentrations [19].
Table 4 Association of eGFR with ADMA concentrations in men and women
Variables model 1 model 2 model 3
β (μmol/L) p value β (μmol/L) p value β (μmol/L) p value
Men (n = 269)
eGFR (mL/min/1.73m2) − 0.0020 <.0001 −0.0018 0.001 −0.0015 0.005
Systolic BP (mmHg) 0.0000 0.955 −0.0001 0.746
Diastolic BP (mmHg) −0.0009 0.292 −0.0004 0.635
Total cholesterol (mg/dL) −0.0001 0.524 −0.0001 0.539
HDL cholesterol (mg/dL) 0.0005 0.333 0.0005 0.351
Diabetes Mellitus 0.0110 0.461 0.0130 0.393
Current smokers (for non-smokers) 0.0227 0.010 0.0224 0.014
Current drinkers (for non-drinkers) −0.0090 0.520 −0.0079 0.574
Age (yr) 0.0015 0.210
BSA −0.0003 0.991
Women (n = 382)
eGFR (mL/min/1.73m2) −0.0009 0.036 −0.0008 0.052 −0.0010 0.039
Systolic BP (mmHg) −0.0001 0.691 0.0000 0.894
Diastolic BP (mmHg) 0.0004 0.521 0.0003 0.713
Total cholesterol (mg/dL) 0.0000 0.884 0.0000 0.895
HDL cholesterol (mg/dL) −0.0005 0.363 −0.0004 0.434
Diabetes Mellitus −0.0112 0.450 −0.0124 0.409
Current smokers (for non-smokers) 0.0231 0.259 0.0238 0.247
Current drinkers (for non-drinkers) −0.0444 0.067 −0.0442 0.071
Age (yr) −0.0005 0.608
BSA 0.0102 0.734
eGFR, estimated glomerular filtration rate; BP, blood pressure; HDL, high-density lipoprotein; BSA, body surface area
Model 1: unadjusted
Model 2: adjusted for blood pressure, total and HDL cholesterol, diabetes mellitus, smoking status, and drinking status
Model 3: adjusted for sex, age, BSA, blood pressure, total and HDL cholesterol, diabetes mellitus, smoking status, and drinking status
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Since our study targeted the elderly, old-age might be
a factor that impacted the association between reduced
kidney function and elevated ADMA concentrations.
According to a paper on clinical guidelines of CKD, a
decline in eGFR in the elderly is an independent pre-
dictor for adverse outcomes because eGFR considers
age, sex, and body size in the equation. This study also
suggested that eGFR is the best measure of kidney func-
tion [13].
This study has some limitations. First, we could not
directly assess GFR. There are several ways to measure
GFR directly, such as using plasma clearance of nonra-
dioactive iohexol [20] and urinary clearance of inulin or
iothalamate [21]. However, because our cohort study
was conducted for the general healthy population and
not for patients with suspicious kidney disease, we esti-
mated kidney function from the CKD-EPI by using only
two variables known, blood urea nitrogen and creatinine
concentrations. Second, we did not assess endothelial
function directly. Plasma ADMA concentration was used
as a marker of endothelial dysfunction in this study. Al-
though the mechanism of causality between ADMA con-
centration and endothelial dysfunction is not clear,
previous evidence supports its existence [4–6]. Third,
serum creatinine concentrations were analyzed by a col-
orimetric Jaffe, Alkaline picrate, kinetic method, but not
standardized by an isotope dilution mass spectrometry
(IDMS) method. IDMS is a technique with proven high
accuracy for which the sources of error are understood
and under control [22]. Since 2017, the IDMS method
has been utilized to measure serum creatinine in Seoul
Clinical Laboratories, which is a research center analyz-
ing blood, urine, DNA, and other human data. There-
fore, our kidney data was standardized by a calibrator
using the high-performance liquid chromatography
(HPLC) candidate reference method at 2012. Lastly, due
to the cross-sectional study design, we only suggest an
association between eGFR and ADMA concentration.
We could not explain a causal relationship and the clear
mechanisms of eGFR and ADMA concentrations. Fur-
ther research should be carried out to determine the
mechanisms.
Although most previous studies have been conducted
for CKD patients, this study did find a significant associ-
ation in general healthy older adults. Thus, we were able
to assess the effect of reduced eGFR on elevated ADMA
plasma concentration in the general elderly population.
Conclusion
Our findings suggest that eGFR reduction may be re-
lated to elevated ADMA plasma concentrations in the
elderly Korean population. Further studies are required
to verify the prospective causal effect of eGFR reduction
on ADMA concentrations in the general population.
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